Efficacy and Response of SARS-CoV-2 Vaccine in Transplant Patients of Solid Organs | Abstract

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Efficacy and Response of SARS-CoV-2 Vaccine in Transplant Patients of Solid Organs

Author(s): Anubha Jain*, Guddi Laishram and Rupesh Shekhawat


Despite the fact that the Coronavirus Severe Acute Respiratory Syndrome (SARS-CoV-2) pandemic has exposed many shortcomings to our health system and society, there have been remarkable scientific achievements: we are now in 2019. Vaccines that cause severe Coronavirus disease can be given to effectively prevent it. Within a year of the outbreak of a pandemic (COVID-19). The outbreak of Coronavirus has a major impact on Solid Organ Transplantation (SOT). Because of the on-going treatment to suppress the immune system of the transplant patients and other medical conditions prevailing in them, SOT patients are at a greater risk and have increase chances of developing COVID-19. SOT recipients have reported mortality rates of over 13% to 30%. The SARS-CoV-2 vaccine has been developed at an unparalleled rate for the COVID-19 pandemic; also 14 SARS-CoV-2 vaccines are currently approved. Solid Organ Transplant recipients (SOTs) are likely to have COVID-19 related problems, so SARS-CoV-2 vaccination is a top priority. With the availability and availability of the Coronavirus Disease 2019 (COVID-19) vaccine, recipients of Solid Organ Transplants are looking forward to a pandemic (SOTR). Antibody responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were seen in general population 1 in early clinical trials. However, it is unclear if and when SOTR will elicit an antibody response to the COVID-19 vaccine. The COVID-19 vaccine response is diminished in therapeutically immunosuppressed transplant recipients. To understand the immune changes that detected inadequate vaccination responses, use longitudinal serological responses to SARS-CoV-2 mRNA vaccination in transplant recipients at baseline levels of circulating T cells and B cell subsets to determine. You have to choose.

Preliminary data indicate that SARS-CoV-2 vaccination is safe in SOT patients (the incidence of adverse events is noted for transplant patients versus general population), but antibody response is low in this group. It is not yet known whether a double dose of the COVID-19 vaccine is sufficient to elicit an immune response in Solid Organ Transplant (SOT) recipients.

Methodology: For the review article, the data has been searched from various sites like PubMed, Science Direct, Google, and other websites involving searches for the following keywords.

Share this article